• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

行动呼吁:持续丙型肝炎病毒学应答背景下的胆管癌——病例报告及文献综述

A Call To Action: Cholangiocarcinoma in the Setting of Sustained Hepatitis C Virologic Response - Case Report and Review of Literature.

作者信息

Shaik Mohammed R, Shaik Nishat A, Bilgrami Zaid, Wheeler Erika, Chow Robert Td

机构信息

Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, United States.

Department of Medicine, Guntur Medical College, Guntur, Andhra Pradesh, India.

出版信息

J Community Hosp Intern Med Perspect. 2023 Jun 29;13(4):35-41. doi: 10.55729/2000-9666.1198. eCollection 2023.

DOI:10.55729/2000-9666.1198
PMID:37868248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10589012/
Abstract

The incidence of cholangiocarcinoma, an aggressive malignancy with poor prognosis, is increasing. Hepatitis B and C have been well established as predisposing factors for this malignancy. The availability and efficacy of treatment for hepatitis C infection has led to a substantial reduction in viral hepatitis-related cholangiocarcinoma mortality. Despite treatment, the potential for developing cholangiocarcinoma continues to exist for patients with underlying cirrhosis. We present a patient who was effectively treated for hepatitis C with direct-acting antiviral therapy eight years prior. He presented with malaise, fatigue, and an unintentional weight loss of 40 pounds. Imaging revealed a metastatic malignancy, and a liver biopsy confirmed the diagnosis of cholangiocarcinoma and the absence of underlying cirrhosis in the background liver. This case highlights the persistent risk of developing cholangiocarcinoma despite achieving sustained virological response to treatment for hepatitis C. We review the associated literature and briefly discuss the predisposing conditions that might result in such an outcome. We also encourage the need for long-term surveillance for such patients and the importance of conducting more multi-center studies to identify at-risk patients and develop cost-effective screening protocols.

摘要

胆管癌是一种侵袭性恶性肿瘤,预后较差,其发病率正在上升。乙型和丙型肝炎已被确认为这种恶性肿瘤的诱发因素。丙型肝炎感染治疗方法的可得性和有效性已使病毒性肝炎相关胆管癌的死亡率大幅降低。尽管进行了治疗,但潜在肝硬化患者发生胆管癌的可能性仍然存在。我们报告一名患者,其八年前接受了直接抗病毒疗法有效治疗丙型肝炎。他出现不适、疲劳,体重意外减轻40磅。影像学检查显示为转移性恶性肿瘤,肝脏活检确诊为胆管癌,且背景肝脏中无潜在肝硬化。该病例突出了尽管丙型肝炎治疗实现了持续病毒学应答,但仍存在发生胆管癌的持续风险。我们回顾了相关文献,并简要讨论了可能导致这种结果的诱发条件。我们还鼓励对此类患者进行长期监测的必要性,以及开展更多多中心研究以识别高危患者并制定具有成本效益的筛查方案的重要性。

相似文献

1
A Call To Action: Cholangiocarcinoma in the Setting of Sustained Hepatitis C Virologic Response - Case Report and Review of Literature.行动呼吁:持续丙型肝炎病毒学应答背景下的胆管癌——病例报告及文献综述
J Community Hosp Intern Med Perspect. 2023 Jun 29;13(4):35-41. doi: 10.55729/2000-9666.1198. eCollection 2023.
2
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联:是否存在联系?
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
3
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.直接作用抗病毒药物治疗后成功的丙型肝炎病毒复发,随后发生肝细胞癌肉瘤样改变:一例报告。
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
4
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.AGA 临床实践更新:口服直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的相互作用:专家综述。
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
5
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.直接作用抗病毒药物治疗实现病毒学应答后丙型肝炎 3 期纤维化患者的肝细胞癌风险。
Liver Int. 2021 Dec;41(12):2885-2891. doi: 10.1111/liv.15032. Epub 2021 Aug 24.
6
Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C.对慢性丙型肝炎进行直接抗病毒治疗并获得持续病毒学应答后的短期组织学评估。
United European Gastroenterol J. 2018 Nov;6(9):1391-1400. doi: 10.1177/2050640618791053. Epub 2018 Jul 19.
7
Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.直接作用抗病毒药物的持续病毒学应答可抑制丙型肝炎病毒感染所致的骨骼肌丢失。
J Gastroenterol Hepatol. 2020 Sep;35(9):1602-1609. doi: 10.1111/jgh.14991. Epub 2020 Feb 16.
8
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗:长期随访
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
9
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.索磷布韦/维帕他韦治疗 1-6 型丙型肝炎病毒感染合并代偿期肝硬化或中重度纤维化患者的效果
Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.
10
Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature.丙型肝炎病毒清除治疗后胆管细胞癌的发生:病例系列及文献复习。
J Med Life. 2022 Oct;15(10):1257-1266. doi: 10.25122/jml-2022-0102.

本文引用的文献

1
[Clinical Features and Treatment for Cholangiolocellular Carcinoma(CoCC)-Report of Three Cases].[胆管细胞癌(CoCC)的临床特征与治疗——三例报告]
Gan To Kagaku Ryoho. 2022 Dec;49(13):1968-1970.
2
Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature.丙型肝炎病毒清除治疗后胆管细胞癌的发生:病例系列及文献复习。
J Med Life. 2022 Oct;15(10):1257-1266. doi: 10.25122/jml-2022-0102.
3
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.
直接作用抗病毒药物治疗实现病毒学应答后丙型肝炎 3 期纤维化患者的肝细胞癌风险。
Liver Int. 2021 Dec;41(12):2885-2891. doi: 10.1111/liv.15032. Epub 2021 Aug 24.
4
Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome.比较直接作用抗病毒治疗丙型肝炎前后的肝活检结果,并与临床结果相关。
Sci Rep. 2021 Jul 15;11(1):14506. doi: 10.1038/s41598-021-93881-7.
5
Intrahepatic Cholangiocarcinoma in a Patient with Hepatitis C: A Cautionary Tale.丙型肝炎患者的肝内胆管癌:一则警示故事
R I Med J (2013). 2020 Jun 1;103(5):30-34.
6
Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.治疗 HCV 可降低病毒相关性肝炎相关的肝相关死亡率:一项 ERCHIVES 研究。
J Hepatol. 2020 Aug;73(2):277-284. doi: 10.1016/j.jhep.2020.02.022. Epub 2020 Mar 5.
7
Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.他汀类药物对肝外胆管癌风险的影响。
Hepatology. 2020 Oct;72(4):1298-1309. doi: 10.1002/hep.31146. Epub 2020 Oct 9.
8
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.口服抗病毒药物治疗后,丙型肝炎相关代偿性晚期慢性肝病患者肝脏相关事件的无创预测。
J Hepatol. 2020 Mar;72(3):472-480. doi: 10.1016/j.jhep.2019.10.005. Epub 2019 Oct 17.
9
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.APASL HCV 指南:DAA 治愈的 HCV 患者应如何监测 HCC 发生和 HBV 再激活。
Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.
10
Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.检测达到持续病毒学应答的患者体内的残留 HCV-RNA 与持续的组织学异常相关。
EBioMedicine. 2019 Aug;46:227-235. doi: 10.1016/j.ebiom.2019.07.043. Epub 2019 Jul 23.